Senior management and key employees in Bactiguard have acquired call options in Bactiguard issued by the main owners, comprising shares corresponding to 4 percent of all shares in Bactiguard

The Board of Directors in Bactiguard Holding AB (publ) has been informed by the company’s main owners, Christian Kinch, Thomas von Koch and Jan Ståhlberg, that senior management and key employees in Bactiguard have acquired call options in Bactiguard issued by the three main owners, comprising shares corresponding to 4 per cent of all shares in Bactiguard.

The company’s main owners have offered senior management (including two board members) and key employees in Bactiguard to acquire call options in Bactiguard issued by the main owners. In total 1 504 795 call options have been acquired, at a price deemed to correspond to the market value of the options. The total number of shares comprised by the issued options corresponds to 4 per cent of all outstanding shares in Bactiguard. The total market value of the options at the time of the transaction has been calculated to SEK 10.4 million, whereof options acquired by the CEO, Anders Göransson, constitute SEK 3 million, options acquired by other members of the executive management constitute SEK 4.2 million, and options acquired by the board members Anna Martling and Magdalena Persson constitute SEK 0.4 million.

Each option entitles to purchase of one Bactiguard Class B share and have a maturity of five years and may be exercised during the period 15–31 May 2027. The exercise price per option is SEK 188, corresponding to 184 per cent of the volume-weighted average price paid for the Bactiguard Class B share on Nasdaq Stockholm during the period 27 April-10 May 2022.

Bactiguard has not been involved in the offer to the senior management and key employees in Bactiguard. The offer has been made by Christian Kinch, Thomas von Koch and Jan Ståhlberg on their own initiative.

The offer does not incur any costs for Bactiguard, nor any share dilution.

For more information, please contact:
Anders Göransson, CEO, phone +46 8 440 58 80
 

About Bactiguard
Bactiguard is a Swedish medical device company with a mission to save lives. To achieve this mission, we develop and supply infection prevention solutions which reduce the risk of infections and the use of antibiotics. This way, we save significant costs for healthcare and the society at large.

The Bactiguard technology is based on a thin noble metal alloy coating that prevents bacterial adhesion and biofilm formation on medical devices. Bactiguard offers the technology through licence agreements and our BIP (Bactiguard Infection Protection) portfolio of products. Urinary catheters with the Bactiguard technology are market leading in the USA and Japan through our licensing partner BD, and in 2021 orthopaedic trauma implants, ZNN Bactiguard, were launched by Zimmer Biomet. Bactiguard's product portfolio also includes a non-alcoholic product line for wound care and disinfection. It effectively kills microbes while being biocompatible and tissue friendly.

Bactiguard is in a strong expansion phase in the markets in Europe, China, India, the Middle East and Southeast Asia through our own product portfolio and by establishing licensing deals in new therapy areas. Bactiguard has about 210 employees around the world. Its headquarters and one of three production facilities are located in Stockholm, the other two in Malaysia. Bactiguard is listed on Nasdaq Stockholm.

Read more about Bactiguard www.bactiguard.com